Stocks / JNJ
JNJ stock forecast
JOHNSON & JOHNSON · Healthcare · Drug Manufacturers - General
Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.
JNJ is not among the 20 largest holdings published for 2026 Q4. See the portfolio
JNJ against the S&P 500
| Period | JNJ | S&P 500 (SPY) |
|---|---|---|
| 1 month | +7.5% | -4.7% |
| 3 months | +0.2% | -4.8% |
| Year to date | +33.9% | +7.9% |
| 1 year | +39.4% | +11.8% |
Total return, dividends included.
Key numbers
| Price | $272.70 |
| Market cap | 656.47 Billion |
| P/E (trailing 12 months) | 40.8 |
| P/S (trailing 12 months) | 6.6 |
| P/B (latest quarter) | 7.6 |
| Gross margin | 67.6% |
| Net profit margin | 16.2% |
| Return on equity | 19.6% |
| Beta | -0.0 |
As of October 21, 2026.
JNJ and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| ABBV | ABBVIE INC | 505.56 Billion | Outperform | JNJ vs ABBV |
| MRK | MERCK & CO INC | 339.66 Billion | Greatly Outperform | JNJ vs MRK |
| AMGN | AMGEN INC | 240.11 Billion | Outperform | JNJ vs AMGN |
| GILD | GILEAD SCIENCES INC | 209.59 Billion | Outperform | |
| PFE | PFIZER INC | 159.94 Billion | Greatly Outperform | |
| BMY | BRISTOL MYERS SQUIBB CO | 121.75 Billion | Greatly Outperform |
Questions
What does the Upfront Investment model say about JNJ?
The model rates JOHNSON & JOHNSON (JNJ) "Outperform" as of November 18, 2026, which means its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the JNJ rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is JNJ in the Upfront Investment model portfolio?
JNJ is not among the 20 largest holdings published for 2026 Q4.
The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.